Avastin fails to win FDA panel support

12/5/2007 | Wall Street Journal (free content), The · NYTimes.com

An FDA advisory panel voted 5-4 Wednesday against approving Genentech's cancer drug Avastin as a first-line treatment for patients with recurrent or metastatic breast cancer. A National Cancer Institute study showed no significant difference in overall survival for patients who took Avastin with Taxol compared to those taking Taxol alone.

View Full Article in:

Wall Street Journal (free content), The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC